Roche delays US launch of Tecentriq SC with Halozyme's ENHANZE to 2024

HALOZYME THERAPEUTICS, INC.

Roche informed Halozyme on Sept 6, 2023 of US launch delay for Tecentriq SC due to required CMC updates.
CMC process updates expected to finish in 2023, enabling potential US launch in 2024.
Ex-US filings for Tecentriq SC remain unaffected by the delay.
Delay could impact Halozyme's royalty revenue from US sales until 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.